Janssen inks potential $1bn deal for IBD drug
Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in a deal worth up to $1 billion. The Johnson & Johnson unit will pay $50 million up front and up to $940 million in development and sales-related payments, plus around 10%-15% royalties on net sales, in a deal to co-develop and market PTG-200.